Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Pascal Poignard

Showing results (11-20 of 84) with videos related to

Pageof 9
Sort By:
Vaccines|April 23, 2025
Pre-Existing Anti-Vector Immunity to Adenovirus-Inspired VLP Vaccines Shows an Adjuvant-Dependent AntagonismSalomé Gallet, Dalil Hannani, Sebastian Dergan-Dylon, et al.
Scientific Reports|October 28, 2014
Toward a more accurate view of human B-cell repertoire by next-generation sequencing, unbiased repertoire capture and single-molecule barcodingLinling He, Devin Sok, Parisa Azadnia, et al.
Journal of Virology|December 13, 2002
Heterogeneity of envelope molecules expressed on primary human immunodeficiency virus type 1 particles as probed by the binding of neutralizing and nonneutralizing antibodiesPascal Poignard, Maxime Moulard, Edwin Golez, et al.
Plos Pathogens|August 12, 2010
A limited number of antibody specificities mediate broad and potent serum neutralization in selected HIV-1 infected individualsLaura M Walker, Melissa D Simek, Frances Priddy, et al.
Vaccine|March 8, 2014
Profiling human antibody responses by integrated single-cell analysisAdebola O Ogunniyi, Brittany A Thomas, Timothy J Politano, et al.
Immunity|November 21, 2015
Identification of Common Features in Prototype Broadly Neutralizing Antibodies to HIV Envelope V2 Apex to Facilitate Vaccine DesignRaiees Andrabi, James E Voss, Chi-Hui Liang, et al.
Plos Pathogens|May 14, 2009
Broadly neutralizing human anti-HIV antibody 2G12 is effective in protection against mucosal SHIV challenge even at low serum neutralizing titersAnn J Hessell, Eva G Rakasz, Pascal Poignard, et al.
Journal of Virology|June 16, 2017
Intrasubtype B HIV-1 Superinfection Correlates with Delayed Neutralizing Antibody ResponseGabriel A Wagner, Elise Landais, Gemma Caballero, et al.
Journal of Virology|August 19, 2011
A panel of IgG1 b12 variants with selectively diminished or enhanced affinity for Fcγ receptors to define the role of effector functions in protection against HIVBrian Moldt, Niccole Schultz, D Cameron Dunlop, et al.
Plos Computational Biology|September 26, 2014
IDEPI: rapid prediction of HIV-1 antibody epitopes and other phenotypic features from sequence data using a flexible machine learning platformN Lance Hepler, Konrad Scheffler, Steven Weaver, et al.
Pageof 9

Showing results (11-20 of 84) with videos related to

Sort By:
Pageof 9
Vaccines|April 23, 2025
Pre-Existing Anti-Vector Immunity to Adenovirus-Inspired VLP Vaccines Shows an Adjuvant-Dependent AntagonismSalomé Gallet, Dalil Hannani, Sebastian Dergan-Dylon, et al.
Scientific Reports|October 28, 2014
Toward a more accurate view of human B-cell repertoire by next-generation sequencing, unbiased repertoire capture and single-molecule barcodingLinling He, Devin Sok, Parisa Azadnia, et al.
Journal of Virology|December 13, 2002
Heterogeneity of envelope molecules expressed on primary human immunodeficiency virus type 1 particles as probed by the binding of neutralizing and nonneutralizing antibodiesPascal Poignard, Maxime Moulard, Edwin Golez, et al.
Plos Pathogens|August 12, 2010
A limited number of antibody specificities mediate broad and potent serum neutralization in selected HIV-1 infected individualsLaura M Walker, Melissa D Simek, Frances Priddy, et al.
Vaccine|March 8, 2014
Profiling human antibody responses by integrated single-cell analysisAdebola O Ogunniyi, Brittany A Thomas, Timothy J Politano, et al.
Immunity|November 21, 2015
Identification of Common Features in Prototype Broadly Neutralizing Antibodies to HIV Envelope V2 Apex to Facilitate Vaccine DesignRaiees Andrabi, James E Voss, Chi-Hui Liang, et al.
Plos Pathogens|May 14, 2009
Broadly neutralizing human anti-HIV antibody 2G12 is effective in protection against mucosal SHIV challenge even at low serum neutralizing titersAnn J Hessell, Eva G Rakasz, Pascal Poignard, et al.
Journal of Virology|June 16, 2017
Intrasubtype B HIV-1 Superinfection Correlates with Delayed Neutralizing Antibody ResponseGabriel A Wagner, Elise Landais, Gemma Caballero, et al.
Journal of Virology|August 19, 2011
A panel of IgG1 b12 variants with selectively diminished or enhanced affinity for Fcγ receptors to define the role of effector functions in protection against HIVBrian Moldt, Niccole Schultz, D Cameron Dunlop, et al.
Plos Computational Biology|September 26, 2014
IDEPI: rapid prediction of HIV-1 antibody epitopes and other phenotypic features from sequence data using a flexible machine learning platformN Lance Hepler, Konrad Scheffler, Steven Weaver, et al.
Pageof 9